Table 1.
Baseline characteristics of the subjects.
| Characteristics | Controls (n = 13) | COPD group (n = 10) |
|---|---|---|
| Demography | ||
| Age (years) | 59 (5) | 60 (8) |
| Sex (M/F) | 8/5 | 7/3 |
| Weight (kg) | 75.4 (12.3) | 76.2 (19.0) |
| Spirometry | ||
| FEV1 (l) | 3.12 (0.66) | 1.03 (0.39) |
| FEV1 (% predicted) | 109 (15) | 41 (17) |
| FVC (l) | 3.97 (0.71) | 2.17 (0.87) |
| FEV1/FVC (%) | 79 (5) | 42 (15) |
| TLC (l) | 5.6 (1.44) | 7.48 (3.21) |
| TLC (% predicted) | 93 (15) | 125 (30) |
| KCO | 1.49 (0.35) | 0.83 (0.33) |
| KCO (% predicted) | 104 (25) | 57 (24) |
| Daily inhaled steroid dose (µg)* | 900 (0–2000) | |
| Smoking history | ||
| No of pack years* | 0 (0–10) | 37.5 (15–140) |
Data are mean (s.d.), except for
*
which denotes median (range). Inhaled steroid dose is the dose of beclomethasone diproprionate or budesonide at entry into the study.